Oncology NEWS International. Vol. 19 No. 8
Focus on Hematology
Second-generation TKIs poised to succeed imatinib in newly diagnosed CML
By MARY BETH NIERENGARTEN | August 10, 2010
Imatinib (Gleevec), the first-line standard of care in chronic myeloid leukemia, will become a generic drug in 2015, so the race is on to find a second generation of tyrosine kinase inhibitors (TKIs) that can do the job just as well.
The Launch and Uptake of Nine Emerging Therapies Will Drive the Prostate Cancer Drug Market to More Than Double to $8.4 Billion in 2019
Emerging Therapies, Most Notably Dendreon's Provenge, Will Account For More Than Half of the Total Prostate Cancer Market in 2019, According to Findings from Decision Resources
WALTHAM, Mass., July 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds...
FDA Sets Priority Review Schedule for BMS and Otsuka’s sNDA for Sprycel as First-Line CML Therapy
FDA accepted an sNDA for Bristol-Myers Squibb (BMS) and Otsuka Pharmaceutical’s chronic myeloid leukemia (CML) drug, Sprycel®, and has granted the application priority review status. The sNDA specifically relates to use of the BCR-ABL inhibitor for the treatment of adult patients with newly diagnosed CML in chronic phase. The projected FDA action data is October...
* Sprycel cleared leukemia cells in 77 pct vs 66 pct
* Fewer side-effects than with Gleevec
* Novartis drug Tasigna tops Gleevec in similar study (Recasts, updates with quote from meeting)
By Bill Berkrot
NEW YORK, June 5 (Reuters) - Bristol-Myers Squibb's (BMY.N) cancer drug Sprycel was superior to the highly effective Gleevec in treating newly diagnosed patients with chronic myeloid leukemia, researchers...
ZURICH, June 4 (Reuters) - Swiss drug-maker Novartis (NOVN.VX) said 18-month results from a study confirmed its Tasigna cancer drug is more efficient in slowing down chronic myeloid leukaemia (CLM) than older medicine Glivec.
